Philipp Kuhn | VP Services & Operations
Yumab GmbH

Festival of Biologics Day 3 @ 11:50

Next-generation TCR-like antibodies with improved specificity profiles

In this talk, we introduce YUMAB’s advanced TCR-mimic discovery platform addressing the off-target-pHLA binding challenge. Employing our technology, we discovered highly specific, human antibodies against the cancer antigen WT1. Our antibodies outperform established references (e.g., 11D06, ESK1) in affinity and specificity without additional engineering. As a next step, we integrate these TCR-like antibodies with proprietary anti-CD3 antibodies to develop bispecific T cell engagers (“safeTY-engagers”). This innovative approach, funded by the BMBF (safeTY-engager, ID: 16LW0341), aims to enhance precision and safety in cancer immunotherapy.

Philipp Kuhn, VP Services & Operations, Yumab GmbH

×

Philipp Kuhn / Next-generation TCR-like antibodies with improved specificity profiles

Philipp Kuhn, VP Services & Operations,
Yumab GmbH

2024Yumab GmbH VP Services & Operations2016-2024Yumab GmbH Project manager2014-2016Technical University of BraunschweigPhD student, Department of Biotechnology.2008-2014University of Heidelberg Study of Molecular Biotechnology (Bsc/Msc).

Close